title: Fetal erythropoiesis and the diagnosis and treatment of hemoglobin disorders in the fetus and child.
abstract: Although synthesis of adult hemoglobin (alpha 2 beta 2) is reduced or absent in both alpha and beta thalassemias, these disorders differ in their clinical significance to the fetus and neonate. alpha-Globin synthesis is observed in the yolk sac by 3 weeks of gestation and, by 9 weeks of gestation, alpha-globin represents the main alpha-like hemoglobin in the fetus. By contrast, the switch to beta-globin chain synthesis usually remains incomplete until 1 year after birth. Therefore, the clinical manifestations of homozygous beta-thalassemia may be ameliorated by sustained synthesis of fetal hemoglobin during the first 6 months of life, whereas up until 10 years ago, homozygous alpha-thalassemia was invariably associated with death in utero. More recently, reports of infants with homozygous alpha-thalassemia surviving the neonatal period have emerged, observations particularly relevant to large numbers of immigrants to North America from Southeast Asia, where alpha-thalassemia is common. Studies of patients with the beta-globin disorders thalassemia and sickle cell disease showed that the severity of both disorders is ameliorated by sustained synthesis of fetal hemoglobin into adult life. Hence, treatment for both these disorders has focused on the pharmacological manipulation of fetal hemoglobin. Studies in vitro, in animal models, and in affected patients have shown that several compounds stimulate gamma-globin synthesis and fetal hemoglobin production through a variety of proposed mechanisms. Some of the successes in human trials are outlined herein.
authors.affiliation: Toronto Hospital, General Division, Canada.
authors.forename: N F
authors.initials: NF
authors.lastname: Olivieri
mesh_terms: D000986:Antisickling Agents / Q000627:therapeutic use; D004920:Erythropoiesis / Q000502:physiology*; D005315:Fetal Diseases / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D005333:Fetus / Q000502:physiology*; D005914:Globins / Q000096:biosynthesis; D006453:Hemoglobinopathies / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D017085:alpha-Thalassemia / Q000503:physiopathology
chemical_list: D000986:Antisickling Agents; D005914:Globins; D006918:Hydroxyurea